EGFR and lung carcinoma: Osimertinib exerted growth inhibitory effects on the EGFR mutation-positive lung carcinoma cell lines PC9 and H1975, even with the knockdown of EGFR, and on the EGFR mutation-negative lung carcinoma cell lines A549 and LK2 at high concentrations.